Swedbank AB lowered its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA – Free Report) by 2.8% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 109,409 shares of the company’s stock after selling 3,101 shares during the quarter. Swedbank AB’s holdings in Teva Pharmaceutical Industries were worth $1,972,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Quadrature Capital Ltd bought a new stake in shares of Teva Pharmaceutical Industries in the 4th quarter worth $203,000. Park Avenue Securities LLC bought a new stake in Teva Pharmaceutical Industries in the 1st quarter worth about $248,000. Range Financial Group LLC purchased a new stake in Teva Pharmaceutical Industries in the 1st quarter valued at about $797,000. Atlas Capital Advisors LLC lifted its position in shares of Teva Pharmaceutical Industries by 3,427.6% during the 1st quarter. Atlas Capital Advisors LLC now owns 43,742 shares of the company’s stock worth $617,000 after buying an additional 42,502 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. boosted its stake in shares of Teva Pharmaceutical Industries by 30.3% in the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 206,162 shares of the company’s stock worth $2,909,000 after buying an additional 47,954 shares during the last quarter. 54.05% of the stock is owned by hedge funds and other institutional investors.
Insider Activity
In other Teva Pharmaceutical Industries news, insider Eric A. Hughes sold 24,537 shares of the firm’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $17.25, for a total value of $423,263.25. Following the completion of the transaction, the insider now owns 45,060 shares in the company, valued at $777,285. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.55% of the stock is owned by company insiders.
Analyst Upgrades and Downgrades
Check Out Our Latest Report on Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Price Performance
Shares of NYSE:TEVA opened at $17.96 on Friday. The company has a 50-day moving average price of $17.97 and a two-hundred day moving average price of $16.61. Teva Pharmaceutical Industries Limited has a twelve month low of $8.06 and a twelve month high of $19.08. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 2.52. The firm has a market capitalization of $20.34 billion, a PE ratio of -46.04, a P/E/G ratio of 1.20 and a beta of 0.88.
Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) last released its quarterly earnings data on Wednesday, July 31st. The company reported $0.58 earnings per share for the quarter, beating analysts’ consensus estimates of $0.55 by $0.03. The business had revenue of $4.16 billion during the quarter, compared to analyst estimates of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 2.73% and a positive return on equity of 39.66%. Equities analysts forecast that Teva Pharmaceutical Industries Limited will post 2.33 EPS for the current year.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
See Also
- Five stocks we like better than Teva Pharmaceutical Industries
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Survey Reveals: America’s Most Coveted Businesses in 2024
- Overbought Stocks Explained: Should You Trade Them?
- Top 3 Stocks to Play Oil’s Potential Comeback Rally
- How to Capture the Benefits of Dividend Increases
- Analysts See Growth in CrowdStrike Stock Despite July Setback
Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVA – Free Report).
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.